Clinical trial NCT00964158: Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
Official title: Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Influenza
Keywords: influenza infection
GSK Bio's influenza vaccine GSK2340272A
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2009-08-24
Enrollment: 210
Sex: ALL
Minimum age (years): 3
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.


Eligibility criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
* Children, male or female, aged between 3 and 17 years at the time of the first study vaccination.
* Written informed consent obtained from the subject parent(s) or LAR(s) of the subject. Assent obtained from the subject when applicable.
* Healthy children as established by medical history and clinical examination when entering into the study.
* Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user.

Exclusion Criteria:

* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.
* Clinically or virologically confirmed influenza infection within six months preceding the study start.
* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.
* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.
* Acute disease and/or fever at the time of enrolment
* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.
* Previous administration of any H1N1 A/California-like vaccine.
* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study.
* If the subject is female and if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.
* Any known or suspected allergy to any constituent of influenza vaccines;a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.
* Known use of an analgesic or antipyretic medication within 12 hours prior to first vaccination.
* Child in Care.

Primary outcomes:
measure: Number of Subjects With Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value
timeFrame: At Day 0
measure: Number of Subjects With HI Antibody Concentrations Above the Cut-off Value
timeFrame: At Day 42
measure: Titers for Serum HI Antibodies
timeFrame: At Day 0
measure: Titers for Serum HI Antibodies
timeFrame: At Day 42
measure: Number of Seroconverted (SCR) Subjects in Terms of HI Antibodies
timeFrame: At Day 42
measure: Number of Seroprotected (SPR) Subjects in Terms of HI Antibodies
timeFrame: At Day 42
measure: Seroconversion Factor (SCF) for HI Antibody Titers
timeFrame: At Day 42
Secondary outcomes:
measure: Number of Subjects With HI Antibody Concentrations Above the Cut-off Value
timeFrame: At Days 0, 21, 42 and at Month 12
measure: Titers for Serum HI Antibodies
timeFrame: At Days 0, 21, 42 and at Month 12
measure: Number of Seroconverted (SCR) Subjects in Terms of HI Antibodies
timeFrame: At Days 21, 42 and at Month 12
measure: Number of Seroprotected Subjects in Terms of HI Antibodies
timeFrame: At Days 0, 21, 42 and at Month 12
measure: Seroconversion Factor (SCF) for HI Antibody Titers
timeFrame: At Days 21, 42 and at Month 12
measure: Number of Subjects With Neutralizing Antibody Concentrations Above the Cut-off Value
timeFrame: At Days 0, 21 and 42
measure: Titers for Serum Neutralizing Antibodies
timeFrame: At Days 0, 21 and 42
measure: Number of Subjects With Neutralizing Antibody Concentrations Above the Cut-off Value
timeFrame: At Month 12
measure: Titers for Serum Neutralizing Antibodies
timeFrame: At Month 12
measure: Number of Seroconverted (SCR) Subjects in Terms of H1N1 Neutralizing Antibodies
timeFrame: At Days 21 and 42
measure: Number of Seroconverted (SCR) Subjects in Terms of H1N1 Neutralizing Antibodies
timeFrame: At Month 12
measure: Number of Subjects With Any and Grade 3 Solicited Local Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
measure: Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
measure: Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
timeFrame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
measure: Number of Subjects With Any Medically-attended Events (MAEs)
timeFrame: During the entire study period (from Day 0 up to Month 12)
measure: Number of Subjects With Any Adverse Events of Specific Interest (AESIs), Including Potential Immune-mediated Disease (pIMDs)
timeFrame: During the entire study period (from Day 0 up to Month 12)
measure: Number of Subjects With Normal or Abnormal Biochemical Levels
timeFrame: At Days 0, 21 and 42
measure: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
timeFrame: During the 21-day (Days 0-20) follow-up period after the first vaccination
measure: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
timeFrame: During the 83-day (Days 0-82) follow-up period after the first vaccination and the 62-day (Days 0-61) follow-up period after the second vaccination
measure: Number of Subjects With Serious Adverse Events (SAEs)
timeFrame: During the entire study period (from Day 0 up to Month 12)
Other outcomes:
Locations:
city: Bilbao
country: Spain
facility: GSK Investigational Site
city: Burgos
country: Spain
facility: GSK Investigational Site
city: Madrid
country: Spain
facility: GSK Investigational Site
city: Móstoles/Madrid
country: Spain
facility: GSK Investigational Site
city: Sevilla
country: Spain
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Garcia-Sicilia J, Aristegui J, Omenaca F, Carmona A, Tejedor JC, Merino JM, Garcia-Corbeira P, Walravens K, Bambure V, Moris P, Caplanusi A, Gillard P, Dieussaert I. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies. Hum Vaccin Immunother. 2015;11(10):2359-69. doi: 10.1080/21645515.2015.1063754.
citation: Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, Behre U, Caplanusi A, Vaman T, Dieussaert I. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine. 2011 Jun 10;29(26):4353-61. doi: 10.1016/j.vaccine.2011.04.011. Epub 2011 Apr 17.